Alnylam Pharmaceuticals reported third-quarter 2026 global net product revenue of $1.292 billion, up 52% from a year earlier, with growth led by its transthyretin (TTR) franchise. The company also outlined progress in two clinical programs: it raised the planned enrollment for its Phase 3 nucresiran study in ATTR cardiomyopathy and reported encouraging early results for brezosiran in Huntington’s disease.
Alnylam said it remains on track to meet its 2026 financial guidance. The announcement did not provide the guidance figures or additional earnings measures in the material presented here.
Key details
- Product revenue rose sharply: Global net product revenue was $1.292 billion in the quarter, a 52% increase year over year.
- TTR products drove much of the growth: Total TTR revenue reached $1.15 billion, up 59% from the third quarter of 2025.
- Nucresiran trial enrollment is expanding: Alnylam increased the target enrollment in the Phase 3 TRITON-CM study to 2,250 patients. The company said the study design continues to support an expected launch for the ATTR cardiomyopathy treatment by 2030.
- Brezosiran advances toward later-stage testing: Initial Phase 1 results in patients with Huntington’s disease showed robust target engagement and an encouraging safety and tolerability profile, according to the company. Alnylam expects to begin a pivotal study in 2027.
- Commercial focus remains on AMVUTTRA: Chief Executive Yvonne Greenstreet said the company is working to expand the prescriber base and patient access for AMVUTTRA, its treatment for ATTR amyloidosis.
Plain-English implications
TTR products are the main growth engine identified in the announcement, while the expanded nucresiran study supports Alnylam’s longer-term effort to build on that franchise. Brezosiran remains earlier in development: the reported Phase 1 findings are preliminary, with a pivotal study planned for 2027.